Latest News
Jazz Pharmaceuticals announces positive opinion from CHMP for Zanidatamab in HER2-positive biliary tract cancer
25 April 2025 - Biopharmaceutical company Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced on Friday that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending...
CHMP backs Camurus' Oczyesa for acromegaly treatment in EU
25 April 2025 - Biopharmaceutical company Camurus (NASDAQ STO: CAMX) announced on Friday that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Oczyesa, a long-actin...
InnoCare receives NMPA approval for orelabrutinib as first-line treatment for CLL/SLL in China
25 April 2025 - Biopharmaceutical company InnoCare Pharma (HKEX: 09969) (SSE: 688428) announced on Friday that the China National Medical Products Administration (NMPA) has approved its BTK inhibitor, orelabrutinib, for the first-line treatment of ch...
RaySearch Laboratories announces order from Odense University Hospital for RayStation
25 April 2025 - RaySearch Laboratories AB (STO:RAY.B), a provider of software for radiation therapy, announced on Friday that it has secured an order worth DKK10.5m (approximately SEK15.4m) from Odense University Hospital, part of the South Denmark R...
AbbVie submits TrenibotulinumtoxinE (TrenibotE) Biologics License Application to U.S. FDA to treat glabellar lines
25 April 2025 - AbbVie (NYSE: ABBV), a Chicago-based pharmaceutical company, announced on Thursday that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the...